Thrombosis in myeloma treated with IMiDs
Related Experiment Video
Updated: May 18, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
1Service des Maladies du Sang, Hôpital Huriez, CHRU, Lille France. xavier.leleu@chru-lille.fr
Survival of myeloma patients has improved since the introduction of novel agents in the armamentorium, especially with the Immunomodulator drugs (IMiDs). However, this substantial benefit has been counterbalanced by the dramatic increase of the incidence rate of thromboembolic events, either venous and/or arterial. This observation has made compulsory a prophylactic treatment in myeloma treated with IMiDs. Although guidelines were proposed since, it is clear that several unanswered questions remain, starting with the choice of the thromboprophylaxis and the definition of risk factors. Further studies are warranted to help decide the optimal thromboprophylaxis.
Survival of myeloma patients has improved since the introduction of novel agents in the armamentorium, especially with the Immunomodulator drugs (IMiDs). However, this substantial benefit has been counterbalanced by the dramatic increase of the incidence rate of thromboembolic events, either venous and/or arterial. This observation has made compulsory a prophylactic treatment in myeloma treated with IMiDs. Although guidelines were proposed since, it is clear that several unanswered questions remain, starting with the choice of the thromboprophylaxis and the definition of risk factors. Further studies are warranted to help decide the optimal thromboprophylaxis.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

